In an effort to investigate how the bacteria reacted to each class of anti-TB drug with the goal of making headway toward developing a more-reasoned combination therapy, the researchers studied the proteomic responses of the bacteria to five compounds, namely isoniazid, rifampicin, moxifloxacin, me...
DRUG side effectsHOSPITAL admission & dischargeMYCOBACTERIUM tuberculosisMENINGITISThis case study revolves around a 38-year-old male patient who arrived at the Emergency department complaining of decreased levels of consciousness, agitation, and disorientation. The case follows his a...
director of the Beijing-based Global Health Drug Discovery Institute, said that it is necessary to develop TB medicines with fewer side effects that are easy to apply, making it more likely for patients to adhere to treatment.
Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB. The research, published online ahead of print today in the European Respiratory Journal, suggests a drug called ...
Treatment can disrupt lives and have serious, potentially life-threatening side effects. Rates of drug-resistant TB remain relatively low in the United States, though nearly half a million cases of multidrug resistant TB are estimated to occur globally each year. These cases underscore the need ...
Pyrazinamide: Side effects are similar to those of rifampin, and the dose is based on weight. Ethambutol (Myambutol): The dose is based on weight. Ethambutol can cause vision and hearing problems. If a drug-resistant strain of TB is present, then two other drugs are added to the first tw...
[Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility]. MDR-TB is known to be man-made-disease. Inappropriate treatment of tuberculosis is responsible for the development of MDR-TB. MDR-TB is often accompanied w... Tsuyuguchi - Kekkaku : [Tuberculosis] 被引量: 10发...
Now, a new drug regimen involving fewer pills and side effects is being rolled out in the Asia-Pacific, including the Philippines, Vietnam and Indonesia, where trials have shown a more than 90 percent cure rate after six months. The treatment, known as BPaL, combines the antibiotics bedaquili...
She added: "For MDR-TB and extensively drug-resistant TB (XDR-TB) treatments, governments need to implement scientifically proven, shorter, and patient-centric treatment options with reduced number of drugs and minimal side effects." "Why is there an unacceptably-long delay in rolling out best ...
MSF announced early closure of its phase 2/3 trial of a new TB regimen because an independent DSMB determined that the drug combination in the study regimen was superior to current therapy.